title: ÐÐ»Ð¸ÑÐ½Ð¸Ðµ Ð³ÐµÐ½ÐµÑÐ¸ÑÐµÑÐºÐ¸Ñ Ð²Ð°ÑÐ¸Ð°Ð½ÑÐ¾Ð² 5'-Ð½ÐµÑÑÐ°Ð½ÑÐ»Ð¸ÑÑÐµÐ¼Ð¾Ð¹ Ð¾Ð±Ð»Ð°ÑÑÐ¸ Ð³ÐµÐ½Ð° DRD1 Ð½Ð° ÑÑÐ¾Ð²ÐµÐ½Ñ ÐµÐ³Ð¾ ÑÐºÑÐ¿ÑÐµÑÑÐ¸Ð¸ (Ð¼Ð ÐÐ, Ð±ÐµÐ»Ð¾Ðº) Ð² Ð»Ð¸Ð¼ÑÐ¾ÑÐ¸ÑÐ°Ñ Ð¿ÐµÑÐ¸ÑÐµÑÐ¸ÑÐµÑÐºÐ¾Ð¹ ÐºÑÐ¾Ð²Ð¸ Ð¿ÑÐ¸ ÑÐ¸Ð·Ð¾ÑÑÐµÐ½Ð¸Ð¸
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¼Ð°Ð³Ð¸ÑÑÑÐ°
titleType: Subtitle
title: The genetic variants of the 5'-untranslated region DRD1 gene influence on its expression (mRNA, protein) in peripheral blood lymphocytes in schizophrenia
Creators: name: ÐÑÑÐ°Ð²Ð»ÐµÐ², ÐÐ»ÐµÐºÑÐ°Ð½Ð´Ñ
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2020
Subjects: ÑÐµÑÐµÐ¿ÑÐ¾Ñ Ð´Ð¾ÑÐ°Ð¼Ð¸Ð½Ð° DRD1
Ð¼Ð Ð½Ðº
Ð»Ð¸Ð¼ÑÐ¾ÑÐ¸ÑÑ Ð¿ÐµÑÐ¸ÑÐµÑÐ¸ÑÐµÑÐºÐ¾Ð¹ ÐºÑÐ¾Ð²Ð¸
ÑÐ°ÑÑÑÑÐ¾Ð¹ÑÑÐ²Ð° ÑÐ¸Ð·Ð¾ÑÑÐµÐ½Ð¸ÑÐµÑÐºÐ¾Ð³Ð¾ ÑÐ¿ÐµÐºÑÑÐ°
5â-Ð½ÐµÑÑÐ°Ð½ÑÐ»Ð¸ÑÑÐµÐ¼Ð°Ñ Ð¾Ð±Ð»Ð°ÑÑÑ
dopamine receptor DRD1
mrRna
peripheral blood lymphocytes
schizophrenia spectrum disorders
5âuntranslated region

description: Ð ÑÐ°Ð±Ð¾ÑÐµ Ð±ÑÐ»Ð¸ Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ñ Ð¿Ð¾Ð»Ð¸Ð¼Ð¾ÑÑÐ½ÑÐµ Ð²Ð°ÑÐ¸Ð°Ð½ÑÑ 5â-Ð½ÐµÑÑÐ°Ð½ÑÐ»Ð¸ÑÑÐµÐ¼Ð¾Ð¹ Ð¾Ð±Ð»Ð°ÑÑÐ¸ Ð³ÐµÐ½Ð° ÑÐµÑÐµÐ¿ÑÐ¾ÑÐ° Ð´Ð¾ÑÐ°Ð¼Ð¸Ð½Ð° DRD1 Ð¸ Ð¸Ñ Ð²Ð»Ð¸ÑÐ½Ð¸Ðµ Ð½Ð° ÑÐºÑÐ¿ÑÐµÑÑÐ¸Ñ Ð´Ð°Ð½Ð½Ð¾Ð³Ð¾ Ð³ÐµÐ½Ð° (Ð¼Ð ÐÐ, Ð±ÐµÐ»Ð¾Ðº) Ð² Ð»Ð¸Ð¼ÑÐ¾ÑÐ¸ÑÐ°Ñ Ð¿ÐµÑÐ¸ÑÐµÑÐ¸ÑÐµÑÐºÐ¾Ð¹ ÐºÑÐ¾Ð²Ð¸ (ÐÐÐ) Ñ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ ÑÐ°ÑÑÑÑÐ¾Ð¹ÑÑÐ²Ð°Ð¼Ð¸ ÑÐ¸Ð·Ð¾ÑÑÐµÐ½Ð¸ÑÐµÑÐºÐ¾Ð³Ð¾ ÑÐ¿ÐµÐºÑÑÐ° (Ð Ð¨Ð¡) Ð¸ ÐºÐ¾Ð½ÑÑÐ¾Ð»ÑÐ½Ð¾Ð¹ Ð³ÑÑÐ¿Ð¿Ñ. ÐÐ±Ð½Ð°ÑÑÐ¶ÐµÐ½Ð¾ ÑÐ½Ð¸Ð¶ÐµÐ½Ð¸Ðµ Ð¾ÑÐ½Ð¾ÑÐ¸ÑÐµÐ»ÑÐ½Ð¾Ð³Ð¾ ÑÑÐ¾Ð²Ð½Ñ Ð¼Ð ÐÐ Ð³ÐµÐ½Ð° DRD1 Ñ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ Ð Ð¨Ð¡ Ð² ÑÑÐ°Ð²Ð½ÐµÐ½Ð¸Ð¸ Ñ Ð³ÑÑÐ¿Ð¿Ð¾Ð¹ ÐºÐ¾Ð½ÑÑÐ¾Ð»Ñ, Ð¿ÑÐ¸ ÑÑÐ¾Ð¼ Ð·Ð½Ð°ÑÐµÐ½Ð¸Ñ ÐºÐ¾Ð»Ð¸ÑÐµÑÑÐ²Ð° Ð±ÐµÐ»ÐºÐ° DRD1 Ð´Ð¾ÑÑÐ¾Ð²ÐµÑÐ½Ð¾ Ð½Ðµ ÑÐ°Ð·Ð»Ð¸ÑÐ°Ð»Ð¸ÑÑ Ð¼ÐµÐ¶Ð´Ñ Ð³ÑÑÐ¿Ð¿Ð°Ð¼Ð¸. Ð ÐºÐ¾Ð½ÑÑÐ¾Ð»ÑÐ½Ð¾Ð¹ Ð³ÑÑÐ¿Ð¿Ðµ Ñ Ð½Ð¾ÑÐ¸ÑÐµÐ»ÐµÐ¹ Ð³ÐµÐ½ÐµÑÐ¸ÑÐµÑÐºÐ¾Ð³Ð¾ Ð²Ð°ÑÐ¸Ð°Ð½ÑÐ° ÐÐ rs267410 (C/A) Ð½Ð°Ð±Ð»ÑÐ´Ð°Ð»Ð°ÑÑ ÑÐµÐ½Ð´ÐµÐ½ÑÐ¸Ñ Ðº ÑÐ½Ð¸Ð¶ÐµÐ½Ð¸Ñ ÐºÐ¾Ð½ÑÐµÐ½ÑÑÐ°ÑÐ¸Ð¸ Ð±ÐµÐ»ÐºÐ° DRD1 Ð² ÐÐÐ, Ð² ÑÑÐ°Ð²Ð½ÐµÐ½Ð¸Ð¸ Ñ Ð½Ð¾ÑÐ¸ÑÐµÐ»ÑÐ¼Ð¸ Ð²Ð°ÑÐ¸Ð°Ð½ÑÐ¾Ð² Ð¡Ð Ð¸ Ð¡Ð¡ Ð½Ð° Ð³ÑÐ°Ð½Ð¸ÑÐµ ÑÑÐ°ÑÐ¸ÑÑÐ¸ÑÐµÑÐºÐ¾Ð¹ Ð·Ð½Ð°ÑÐ¸Ð¼Ð¾ÑÑÐ¸ (p=0.059). ÐÑÐ»Ð¾ Ð¿Ð¾ÐºÐ°Ð·Ð°Ð½Ð¾ ÑÐ½Ð¸Ð¶ÐµÐ½Ð¸Ðµ Ð¾ÑÐ½Ð¾ÑÐ¸ÑÐµÐ»ÑÐ½Ð¾Ð³Ð¾ ÑÑÐ¾Ð²Ð½Ñ ÑÐºÑÐ¿ÑÐµÑÑÐ¸Ð¸ DRD1 Ñ Ð½Ð¾ÑÐ¸ÑÐµÐ»ÐµÐ¹ Ð¼Ð¸Ð½Ð¾ÑÐ½Ð¾Ð³Ð¾ Ð°Ð»Ð»ÐµÐ»Ñ G Ð² Ð³Ð¾Ð¼Ð¾- Ð¸ Ð³ÐµÑÐµÑÐ¾Ð·Ð¸Ð³Ð¾ÑÐ½Ð¾Ð¼ ÑÐ¾ÑÑÐ¾ÑÐ½Ð¸Ð¸ rs35916350(Ð¡/G) Ð½Ð° Ð³ÑÐ°Ð½Ð¸ÑÐµ ÑÑÐ°ÑÐ¸ÑÑÐ¸ÑÐµÑÐºÐ¾Ð¹ Ð·Ð½Ð°ÑÐ¸Ð¼Ð¾ÑÑÐ¸ (p=0.053) Ð² ÐºÐ¾Ð½ÑÑÐ¾Ð»ÑÐ½Ð¾Ð¹ Ð³ÑÑÐ¿Ð¿Ðµ. ÐÐ±Ð½Ð°ÑÑÐ¶ÐµÐ½Ð¾ ÑÐ½Ð¸Ð¶ÐµÐ½Ð¸Ðµ ÐºÐ¾Ð½ÑÐµÐ½ÑÑÐ°ÑÐ¸Ð¸ Ð±ÐµÐ»ÐºÐ° DRD1 Ð² ÐÐÐ Ð¿ÑÐ¸ ÑÐµÑÐ°Ð¿Ð¸Ð¸ Ð³Ð°Ð»Ð¾Ð¿ÐµÑÐ¸Ð´Ð¾Ð»Ð¾Ð¼ Ð² ÑÐµÑÐµÐ½Ð¸Ðµ 28 Ð´Ð½ÐµÐ¹ (p=0.001).
description: In this work, we investigated polymorphic variants of the 5'-untranslated region of the dopamine receptor gene (DRD1) and their influence on the expression of this gene (mRNA, protein) in peripheral blood lymphocytes (PBL) of patients with schizophrenia spectrum disorders (SSD) and control group. The mRNA level of DRD1 was significantly lower in patients with SSD compared to the healthy controls (p=0.014), while the DRD1 protein levels were not different between the groups. In control group the genetic variant AA rs267410 (C/A) was associated with a trend of DRD1 protein level reduction in PBL, compared to the CA and CC carriers at the border of statistical significance (p=0.059). In control group minor allele G in homo- and heterozygous state (GG+GC) of rs35916350 (C/G) was associated with a trend to DRD1 mRNA level decrease (p=0.053). Reduction of DRD1 protein level in PBL was detected at haloperidol therapy within 28 days (p=0.001).